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Abstract
Background: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial
comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line
chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly
experimental schedule used, an early safety analysis was planned.
Methods: Patients with ovarian cancer (stage Ic-IV), aged < 75 years, ECOG performance status ≤ 2, were
randomized to carboplatin AUC 5 plus paclitaxel 175 mg/m2, every 3 weeks or to carboplatin AUC 5 plus
pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was
coded according to the NCI-CTC version 2.0.
Results: The pre-planned safety analysis was performed in July 2004. Data from the first 50 patients treated with
carboplatin plus pegylated liposomal doxorubicin were evaluated. Median age was 60 years (range 34–75). Forty-
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three patients (86%) completed 6 cycles. Two thirds of the patients had at least one cycle delayed due to toxicity,
but 63% of the cycles were administered on time. In most cases the reason for chemotherapy delay was
neutropenia or other hematological toxicity. No delay due to palmar-plantar erythrodysesthesia (PPE) was
recorded. No toxic death was recorded. Reported hematological toxicities were: grade (G) 3 anemia 16%, G3/
G4 neutropenia 36% and 10% respectively, G3/4 thrombocytopenia 22% and 4% respectively. Non-haematological
toxicity was infrequent: pulmonary G1 6%, heart rhythm G1 4%, liver toxicity G1 6%, G2 4% and G3 2%.
Complete hair loss was reported in 6% of patients, and G1 neuropathy in 2%. PPE was recorded in 14% of the
cases (G1 10%, G2 2%, G3 2%).
Conclusion: This safety analysis shows that the adopted schedule of carboplatin plus pegylated liposomal
doxorubicin given every 3 weeks is feasible as first line treatment in ovarian cancer patients, although 37% of the
cycles were delayed due to haematological toxicity. Toxicities that are common with standard combination of
carboplatin plus paclitaxel (neurotoxicity and hair loss) are infrequent with this experimental schedule, and skin
toxicity appears manageable.
Background
Ovarian cancer has the highest mortality rate of all gynae-
cologic neoplasms. The high mortality rate may be
explained by the lack of symptoms accompanying early
disease, resulting in patients being diagnosed at an
advanced stage. Furthermore, long term results obtained
with current treatments are limited.
The combination of paclitaxel and cisplatin became
standard first line chemotherapy following the results of
the GOG-111 [1] and subsequent confirmatory trials [2],
because it was more effective than the combination of
cyclophosphamide and cisplatin. Due to its more favour-
able toxicity profile, paclitaxel combined with carboplatin
has replaced paclitaxel and cisplatin as the standard first
line chemotherapy worldwide [3-5]. Debulking surgery
and first line systemic chemotherapy induce complete or
partial response in up to 80% of patients, with about a
25% pathological complete remission rate [4-6]. Unfortu-
nately, recurrences occur in the majority of patients, and
the 5-year survival rate is only 30–50%, largely depending
on the initial FIGO stage.
Anthracyclines were originally used in the first line treat-
ment of ovarian cancer in the '70s, when in vitro experi-
ments showed a dose-response relationship in ovarian
cancer cell lines, and activity against epithelial ovarian
cancer was subsequently proven in clinical trials [7-9]. The
role of anthracyclines in ovarian cancer, though still
debated, has had renewed interest after the availability of
liposomal antracyclines.
Pegylated liposomal doxorubicin (PLD) is a formulation
of doxorubicin encapsulated in liposomes in order to
obtain pharmacokinetic properties not available with
conventional formulation of the drug: lower plasma con-
centration peak, lower clearance, smaller distribution vol-
ume, longer half-life and higher AUC, resulting in a
different toxicity profile [10-15]. The size of the liposomes
allows selective accumulation in the tumor vascular bed
following extravasation through the leaky tumor vascula-
ture [11,12]. In addition, the special coating (pegylation)
of the liposomes is associated with reduced clearance by
the mononuclear phagocyte system, thus helping to main-
tain active drug concentrations for longer periods [10-13].
A phase III randomised trial [16] compared PLD with
standard topotecan, in second line treatment of ovarian
cancer. A 5-year update of this trial has been recently pub-
lished [17], and PLD proved to be statistically superior to
topotecan in terms of overall survival. Furthermore, the
analysis conducted in the subgroup of "platinum-sensi-
tive" patients showed a particularly significant advantage
for PLD compared to topotecan in this group. Following
these results, PLD is now considered the drug of choice for
the treatment of relapsed ovarian cancer in terms of activ-
ity, toxicity and cost benefits. A phase II trial has recently
shown that the combination of carboplatin and PLD
given every 4 weeks is highly effective in recurrent plati-
num-sensitive ovarian cancer [18]. These data represent a
strong rationale for testing PLD in the first line treatment
of ovarian cancer.
The MITO-2 (Multicentre Italian Trials in Ovarian cancer)
study is a randomized phase III study comparing carbopl-
atin plus paclitaxel to carboplatin plus PLD in first-line
treatment of ovarian cancer patients. The primary end-
point is progression-free survival. The secondary end-
points are toxicity, objective response rate, quality of life
and overall survival. In both arms chemotherapy is
administered every 3 weeks. Due to the paucity of pub-
lished safety data on the 3-weekly schedule adopted for
the combination of carboplatin and PLD, an early safety
analysis had been planned and the results are reported in
this paper.BMC Cancer 2006, 6:202 http://www.biomedcentral.com/1471-2407/6/202
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Methods
Patient randomization in the MITO-2 trial started in Jan-
uary 2003. The protocol was approved by the Ethics Com-
mittee of each participating center. Written informed
consent was obtained from each enrolled patient, prior to
study entry. Patients with cytologic or histological diagno-
sis of epithelial ovarian carcinoma (stage Ic-IV), and an
Eastern Cooperative Oncology Group (ECOG) perform-
ance status ≤ 2 were eligible. Exclusion criteria were age ≥
75 years, prior or concurrent malignant cancer (except for
non-melanoma skin cancer and for in situ carcinoma of
the uterine cervix, if adequately treated), brain metastases,
inadequate bone marrow function (neutrophils <2,000/
mm3 or platelets <100,000/mm3); abnormal renal func-
tion (total serum creatinine level > 1.25 the upper normal
limit), abnormal liver function (sAST or sALT or total
serum bilirubin levels > 1.25 the upper normal limit,
except if caused by liver metastases), heart disease (heart
failure, heart attack in the previous 6 months, atrio-ven-
tricular block of any degree, serious arrhythmia).
Patients in the standard arm received carboplatin, area
under curve (AUC) 5, intravenously (i.v.), plus paclitaxel,
175 mg/m2, i.v. in a 3-hour infusion, both drugs on day 1,
every 21 days. Patients in the experimental arm received
carboplatin AUC 5 i.v. and PLD [Caelyx®], 30 mg/m2,
both drugs on day 1, every 21 days. Chemotherapy was
administered for a maximum of 6 cycles. Carboplatin was
dosed in accordance with the Calvert formula [19], and
administered in 250 ml physiologic solution, over 30
minutes. PLD was administered after carboplatin infu-
sion, in 250 ml 5% glucosate solution, over 1 hour.
Treatment toxicity and adverse events were coded accord-
ing to the Common Toxicity Criteria (CTC) of the
National Cancer Institute (NCI), version 2.0 [20].
Criteria for retreatment were: neutrophils ≥ 1,500/mm3,
platelets ≥ 100,000/mm3, Hgb ≥ 9 g/dl, absence of organ
toxicity ≥ 2 (with the exclusion of hair loss). If these min-
imum conditions were not met, the cycle was postponed
by 7 days for a maximum of 2 weeks. If the treatment was
delayed for more than 2 weeks, chemotherapy was dis-
continued due to unacceptable prolonged toxicity. After
the first 3 cycles, in the absence of unacceptable toxicity,
patients with objective response or stable disease received
a further 3 cycles, for a maximum number of six cycles.
A 20% dose reduction was planned for grade 4 neutrope-
nia lasting more than 7 days, grade 3 thrombocytopenia
lasting more than 7 days, or neurotoxicity. In case of cre-
atinine clearance < 60 ml, the dose of carboplatin was
reduced from AUC 5 to AUC 4. In case of grade 2 or higher
palmar-plantar erythrodysesthesia (PPE), chemotherapy
was delayed for up to 2 weeks, until recovery to grade 0–
1, and then resumed with a 25% dose reduction. If cuta-
neous toxicity had not recovered after 2 weeks, PLD was
withdrawn.
No prophylactic use of G-CSF was recommended. Thera-
peutic and prophylactic use of G-CSF was allowed for
febrile or afebrile grade 4 neutropenia.
Complete blood counts were performed at baseline and
weekly. Laboratory exams (sAST, sALT, total serum pro-
tein, albumin, bilirubinaemia, alkaline phosphatase, lac-
tate dehydrogenase, creatininaemia, blood urea nitrogen,
glycaemia, uricaemia, serum electrolytes) and urinalysis
were planned baseline, and then repeated before each
cycle and 3 weeks after the end of the last cycle.
A preplanned safety analysis was performed in July 2004.
The safety analysis was planned to be descriptive and was
not driven by a pre-stated hypothesis and consequent sta-
tistical plan. A sample size of 50 patients was arbitrarily
chosen, and the first 50 patients assigned to CLD arm and
receiving at least one dose of experimental drugs were
considered for this safety analysis.
Results
Main baseline characteristics of the patients are reported
in table 1. Median age was 60 years (range 34–75). All but
two patients had a good ECOG performance status (0 or
1). Almost half of the patients were optimally debulked.
Forty-three patients (86%) completed the planned
number of cycles. Of the remaining seven patients, chem-
otherapy was interrupted before completion for progres-
sive disease or worsening of disease symptoms (5 cases),
for patient's refusal (1) and for prolonged toxicity (1).
Three patients interrupted pegylated liposomal doxoru-
bicin, continuing carboplatin, after the first dose: 1
patient for grade 3 allergy, and 2 patients for prolonged
neutropenia. Four patients had a dose reduction of lipo-
somal doxorubicin because of myelotoxicity (3 patients
after 4 cycles, and 1 patient after 5 cycles).
Thirty-four patients (68%) delayed at least one cycle due
to toxicity. Reasons for chemotherapy delays are detailed
in table 2. In most cases, the reason was sustained neutro-
penia or other hematological toxicity. No delay due to
cutaneous toxicity was recorded. Overall, 37% of the
cycles were delayed.
Details of worst haematological and non-haematological
toxicities are reported in table 3. No toxic death was
recorded. Grade 3 anemia was reported in 8 patients
(16%), with 6 patients receiving transfusions. Grade 3/4
neutropenia was observed in 36% and 10% of patientsBMC Cancer 2006, 6:202 http://www.biomedcentral.com/1471-2407/6/202
Page 4 of 8
(page number not for citation purposes)
respectively. Grade 3/4 thrombocytopenia occurred in
22% and 6% of patients respectively, and in all cases was
asymptomatic and did not require platelet transfusion.
Allergy was reported in 5 patients (10%), leading to treat-
ment withdrawal in 1 case.
Organ toxicity was infrequent: grade 1 pulmonary in 3
patients (6%), grade 1 heart rhythm in 2 patients (4%),
liver toxicity in 6 patients (grade 1, 6%; grade 2, 4%; and
grade 3, 2%). Complete hair loss was reported in 3
patients. Only 1 patient experienced grade 1 neuropathy.
Palmar-plantar erythrodysesthesia was recorded in 14%
of the patients (grade 1, 10%; grade 2, 2%; grade 3, 2%).
The phase III trial is ongoing; as of January 2006, 395
patients have been enrolled.
Discussion
Pegylated liposomal doxorubicin is considered to be one
of the more active drugs in ovarian cancer. This formula-
tion has significant advantages in terms of tolerability
compared to conventional doxorubicin: the most fre-
quent toxicities consist of cutaneous and mucosal toxicity
(hand-foot syndrome and stomatitis), with a very low rate
of nausea, hair loss, extravasation-related necrosis or
reduction in the ventricular ejection fraction [15-17].
When given as a single agent, the drug is usually adminis-
tered every 4 weeks. A phase II trial conducted in France,
the results of which were first presented at ASCO 2004
[18], analysed the combination of PLD and carboplatin,
in patients with platinum-sensitive recurrent ovarian can-
cer. Carboplatin was administered at AUC 5, and lipo-
somal doxorubicin at the dose of 30 mg/m2, both drugs
given every 4 weeks. The combination showed a very high
rate of activity (objective response rate 68%), and a
favourable toxicity profile.
The proven efficacy of liposomal doxorubicin in second
line treatment, and the possibility of easily combining it
with carboplatin, encouraged us to test the efficacy of the
combination of carboplatin and pegylated liposomal dox-
orubicin in first line treatment of patients with ovarian
tumour in a phase III multicentric trial comparing it with
standard chemotherapy (carboplatin plus paclitaxel). In
order to maintain the full dose of carboplatin we chose a
3-weekly schedule of carboplatin and PLD.
Our data show that this schedule is feasible and has a
favourable toxicity profile. Anemia, thrombocytopenia,
Table 2: Causes of chemotherapy delays due to toxicity
Cycle 2 (49 pts) Cycle 3 (47 pts) Cycle 4 (46 pts) Cycle 5 (44 pts) Cycle 6 (43 pts) Overall
Neutropenia 10 11 3 7 8 39
Thrombocytopenia - 4 2 4 4 14
Neutropenia + 
Thrombocytopenia
22533 15
Anemia - 2 1 - 1 4
Anemia + Neutropenia + 
Thrombocytopenia
--1-1 2
Liver toxicity 1 1 2 1 1 6
F e v e r ---1- 1
Other (not specified) 1 - - 1 4 6
Total 14 (28.6%) 20 (42.6%) 14 (30.4%) 17 (38.6%) 22 (51.2%) 87/229 
(37%)
Table 1: Baseline characteristics of patients (n = 50)
Age (years) Median 60
Range 34–76
Residual disease Absent 17 (34%)
≤ 1 cm 6 (12%)
> 1 cm 23 (46%)
Surgery not performed 4 (8%)
Stage IC 3 (6%)
II 6 (12%)
III 29 (58%)
IV 12 (24%)
PS 03 0 ( 6 0 % )
11 8 ( 3 6 % )
22 ( 4 % )
Grading 12 ( 4 % )
21 4 ( 2 8 % )
32 2 ( 4 4 % )
41 2 ( 2 4 % )
Histologic type Serous 30 (60%)
Mucinous 3 (6%)
Endometrioid 7 (14%
Undifferentiated 3 (6%)
Clear cell 1 (2%)
Mixed 4 (8%)
Other 2 (4%)
PS = Performance StatusBMC Cancer 2006, 6:202 http://www.biomedcentral.com/1471-2407/6/202
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and neutropenia were the most frequent toxicities, but no
case of febrile neutropenia was recorded, and no case of
thrombocytopenia was symptomatic. Though 68% of the
patients had at least one cycle delayed, most often due to
persistent neutropenia at day 21, most of the cycles were
still given on time. Non-hematological toxicity of the
combination appears to be different from the toxicity
expected with carboplatin plus paclitaxel, with markedly
less neurotoxicity and hair loss, and a higher incidence of
mild skin toxicity. The limited incidence and severity of
PPE clearly indicates that skin toxicity is significantly less
frequent at this dose compared to single agent PLD when
given at higher doses. Overall, our toxicity data compare
favourably with the results reported in the literature in
platinum-sensitive recurrent disease [18,21]. The main
toxic effect recorded by the French group was myelosup-
pression, with the same proportion of grade 3–4 neutro-
penia, and slightly more anemia (grade 3 34%), and
thrombocytopenia (grade 3–4 31%), probably as a conse-
quence of the second-line setting. delay in the administra-
tion of chemotherapy was necessary in that study,
although less frequently (30% patients) due to the every
4-weeks schedule.
Our study shows that the non-hematological toxicity pro-
file of carboplatin and PLD is particularly safe. The hema-
tologic toxicities are associated with a significant number
of delays in chemotherapy administration for neutrope-
nia and thrombocytopenia, though no cases of febrile
neutropenia or symptomatic thrombocytopenia were
reported. The low rate of neurotoxicity is interesting, given
that neurotoxicity is a major factor in non compliance
with standard first line chemotherapy. In addition, the
low rate of hair loss could represent a significant advan-
tage compared to the standard regimen of carboplatin
plus paclitaxel.
Conclusion
The combination of carboplatin and pegylated liposomal
doxorubicin, in an every-3-week schedule, can be safely
Table 3: Worst toxicity per patient (n = 50)
Toxicity Worst NCI – CTC grade Number of patients (%)
01 2 3 4 5
Anemia 15 (30%) 8 (16%) 19 (38%) 8 (16%) - -
Leukopenia 12 (24%) 11 (22%) 19 (38%) 6 (12%) 2 (4%) -
Neutropenia 11 (22%) 5 (10%) 11 (22%) 18 (36%) 5 (10%) -
Febrile neutropenia 50 (100%) - - - - -
Neutropenic infection 50 (100%) - - - - -
Non neutrop. infection 49 (98%) - 1 (2%) - - -
Platelets 25 (50%) 7 (14%) 5 (10%) 11 (22%) 2 (4%) -
Platelet transfusion 50 (100%) - - - - -
RBC transfusion 47 (94%) - - 3 (6%) - -
Allergy 45 (90%) 2 (4%) 1 (2%) 2 (4%) - -
Bleeding 50 (100%) - - - - -
Fatigue 27 (54%) 13 (26%) 10 (20%) - - -
Heart rhythm 48 (96%) 2 (4%) - - - -
Cardiovascular 48 (96%) 1 (2%) - 1 (2%) - -
Pulmonary 47 (94%) 3 (6%) - - - -
Fever 48 (96%) 2 (4%) - - - -
Weight loss 48 (96%) 1 (2%) 1 (2%) - - -
Hair loss 40 (80%) 7 (14%) 3 (6%) - - -
Local reaction 49 (98%) 1 (2%) - - - -
Skin (including PPE) 43 (86%) 5 (10%) 1 (2%) 1 (2%) - -
Anorexia 44 (88%) 4 (8%) 2 (4%) - - -
Constipation 35 (70%) 9 (18%) 6 (12%) - - -
Diarrhoea 49 (98%) 1 (25) - - - -
Nausea 27 (54%) 16 (32%) 6 (12%) 1 (2%) - -
Vomiting 38 (76%) 8 (16%) 2 (4%) 2 (4%) - -
Stomatitis 42 (84%) 4 (8%) 4 (8%) - - -
Liver 44 (88%) 3 (6%) 2 (4%) 1 (2%) - -
Neuropathy 49 (98%) 1 (2%) - - - -
Kidney 49 (98%) 1 (2%) - - - -
Other 47 (94%) 2 (4%)* - 1 (2%)** - -
RBC = red blood cell; PPE = palmar-plantar erythrodysesthesia
*hyperglycemia (1 patient); epigastric pain (1 patient); ** abdominal painBMC Cancer 2006, 6:202 http://www.biomedcentral.com/1471-2407/6/202
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given as first line treatment of patients with ovarian can-
cer. The MITO-2 study continues the planned enrollment,
and its results will provide useful information regarding
the future role of this combination for these patients.
Competing interests
Sandro Pignata and Francesco Perrone received in the past
five years grants from Schering Plough. The other Authors
declare that they have no competing interests.
Authors' contributions
SP and FP projected the trial, participated in its design and
coordination;
SP, MDM and FP drafted the manuscript;
SP, GS, AS, EB, PS, RDV, ER, VG, DN, FDG, EN, EG, PM,
AMDA, RS and CP treated the patients, collected the clin-
ical data useful for the analysis and revised the article crit-
ically for important intellectual content;
MDM, FP, GS and AA performed the analysis of the data.
All authors read and approved the final manuscript.
Appendix
Participating MITO-2 Institutions and coauthors
National Cancer Institute, Naples (Medical Oncology B: S
Pignata, C Pisano, RV Iaffaioli; Ginecology: S Greggi;
Medical Oncology C: E Rossi; Clinical Trials Unit: F Per-
rone, M Di Maio, E De Maio, A Morabito, G De Feo, R
D'Aniello);
Department of Medicine and Public health, Second Uni-
versity of Naples, Naples, Italy (C Gallo, G Signoriello, A
Annunziata, P Chiodini);
Gynecologic Oncology Unit, Catholic University of the
Sacred Heart, Rome-Campobasso (G Scambia, G Fer-
randina, D Lorusso, A Di Stefano);
Medical Oncology A, Regina Elena Institute, Rome, Italy
(A Savarese, F Cognetti, A. Felici);
Medical Oncology C, National Cancer Institute – Centro
di Riferimento Oncologico, Aviano (PN), Italy (R Sorio, S
Scalone, E Campagnutta);
Medical Oncology, Fatebenefratelli Hospital, Rome, Italy
(E Breda, V Zagonel, R Bompiani);
Malzoni Clinic, Avellino (C Malzoni, M Malzoni, A. Ver-
naglia Lombardi);
Medical Oncology I, La Maddalena Clinic, Palermo, Italy
(V Gebbia, R Agueli, A Testa);
Gynecologic Oncology, M. Ascoli Hospital, Palermo, Italy
(P Musso, L Segreto, R Demma);
Gynecology, Cannizzaro Hospital, Catania, Italy (P
Scollo, G Scibilia, E Lomeo);
Medical Oncology, Ospedali Riuniti, Reggio Calabria,
Italy (M Nardi, P Del Medico, D Azzarello);
Medical Oncology, S. Chiara Hospital, Trento, Italy (E
Galligioni, A Ferro);
Oncology Institute, Bari, Italy (V Lorusso, A Latorre);
Medical Oncology, S. Bortolo Hospital, Vicenza, Italy (R
De Vivo);
Medical Oncology, Umberto I Civil Hospital, Nocera Infe-
riore (SA), Italy (AM D'Arco, A Fabbrocini);
Bellaria Hospital, Bologna, Italy (L Crinò, S Rimondini);
Ramazzini Hospital, Carpi (MO), Italy (F Artioli, L Scal-
triti);
Medical Oncology, Fatebenefratelli Hospital, Benevento,
Italy (A Febbraro, MC Merola);
Medical Oncology, S. Massimo Hospital, Penne (PE), Italy
(D Natale, C Chiapperino);
Civil Hospital, Faenza (RA), Italy (S Tamberi, A Gambi);
Gynecologic Unit CHC, Maternidade Bissaya – Barreto,
Coimbra, Portugal (MO Campos, IM Henriques);
University of Palermo, Policlinico Giaccone, Palermo,
Italy (N Gebbia, MR Valerio);
Medical Oncology, Carlo Poma Hospital, Mantova, Italy
(E Aitini, G Cavazzini);
Ospedale degli Infermi, Rimini – Cattolica, Italy (A
Ravaioli, G Oliverio);
Gynecology, Ospedali Riuniti, Bergamo, Italy (L Frigerio,
L Carlini);
Medical Oncology, University of Cagliari, Cagliari, Italy
(B Massidda);
Ginecology, S Anna Hospital, Turin, Italy (S Danese);BMC Cancer 2006, 6:202 http://www.biomedcentral.com/1471-2407/6/202
Page 7 of 8
(page number not for citation purposes)
Medical Oncology, S. Giuseppe Moscati Hospital, Avel-
lino, Italy (F Del Gaizo);
Medical and Experimental Oncology Unit, Oncology
Institute, Bari, Italy (E Naglieri);
Medical Oncology, Mariano Santo Hospital, Cosenza,
Italy (R Biamonte);
Miulli hospital, Acquaviva delle Fonti (BA), Italy (G Net-
tis);
S. Anna Hospital, Ferrara, Italy (M Marzola);
Cotugno Hospital, Naples, Italy (V Montesarchio);
Budrio Bentivoglio, Italy (V Arigliano);
Pierantoni Hospital, Forlì, Italy (N Riva);
Gynecology, Second University of Naples, Italy (GC
Balbi).
Acknowledgements
The authors thank Giuliana Canzanella, Federika Crudele, Fiorella Romano, 
Giovanni de Matteis and Marzia Falanga for their help in data management.
This work was partially supported by the Associazione Italiana per la 
Ricerca sul Cancro (AIRC).
Pegylated liposomal doxorubicin has been supplied by Schering Plough.
Massimo Di Maio is recipient of a Fondazione Italiana per la Ricerca sul Can-
cro (FIRC) fellowship.
This work have been partially presented at the 2005 meeting of American 
Society of Clinical Oncology (Orlando, FL), as poster discussion.
References
1. Mc Guire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look
KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cis-
platin compared with placlitaxel and cisplatin in patients
with stage III and stage IV ovarian cancer.  N Engl J Med 1996,
334:1-6.
2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E,
Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swen-
erton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA,
Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron
B, Pecorelli S: Randomized intergroup trial of cisplatin-paclit-
axel versus cisplatin-cyclophosphamide in women with
advanced epithelial ovarian cancer: three-year results.  J Natl
Cancer Inst 2000, 92:699-708.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger
RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic
Oncology Group: Phase III trial of carboplatin and paclitaxel
compared with cisplatin and paclitaxel in patients with opti-
mally resected stage III ovarian cancer: a Gynecologic
Oncology Group study.  J Clin Oncol 2003, 21:3194-3200.
4. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C,
de Swart CA, Hirsch FR, Lund B, van Houwelingen HC: Exploratory
phase III study of cisplatin and paclitaxel versus carboplatin
and paclitaxel in advanced ovarian cancer.  J Clin Oncol 2000,
18:3084-92.
5. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S,
Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U,
Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemein-
schaft Gynakologische Onkologie Ovarian Cancer Study Group: A
randomized clinical trial of cisplatin/paclitaxel versus carbo-
platin/paclitaxel as first-line treatment of ovarian cancer.  J
Natl Cancer Inst 2003, 95:1320-29.
6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ:
Survival effect of maximal cytoreductive surgery for advance
ovarian cancer in the platinum era: a metanalysis.  J Clin Oncol
2002, 20:1248-59.
7. Ozols RF, Willson JK, Weltz MD, Grotzinger KR, Myers CE, Young
RC: Inhibition of human ovarian cancer colony formation by
Adriamicin and its metabolites.  Cancer Res 1980, 40:4109-12.
8. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus
cisplatin versus cyclophosphamide, doxorubicin and cisplatin
chemotherapy of ovarian carcinoma.  J Clin Oncol 1991,
9:1668-1674.
9. A'Hern R, Gore ME: The impact of doxorubicin on survival in
advanced ovarian cancer.  J Clin Oncol 1995, 13:726-32.
10. Vaage J, Donovan D, Mayhew E, Abra R, Huang A: Therapy of
human ovarian carcinoma xenografts using doxorubicin
encapsulated in sterically stabilized liposomes.  Cancer 1993,
72:3671-75.
11. Sakakibara T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ,
Bankert RB: Doxorubicin encapsulated in strerically stabilized
liposomes is superior to free drug or drug-containing con-
ventional liposomes at suppressing growth and metastases
of human lung tumors xenografts.  Cancer Res 1996, 56:3743-6.
12. Vaage J, Donovan D, Uster P, Working P: Tumor uptake of doxo-
rubicin in polyethylene glycol-coated liposomes and thera-
peutic effect against a xenografted human pancreatic
carcinoma.  Br J Cancer 1997, 75:482-6.
13. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M,
Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA,
Morrow CP, Paradiso LJ, Liang LJ: Phase II study of liposomal
doxoribicin in refractory ovarian cancer. Antitumor activity
and toxicity modification by liposomal encapsulation.  J Clin
Oncol 1997, 15:987-93.
14. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman
C, Rosales R, Sharpington T: Phase II study of liposomal doxoru-
bicin in platinum-paclitaxel refractory epithelial ovarian can-
cer.  J Clin Oncol 2000, 18:3093-100.
15. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L,
Roman L, Morrow CP, Burnett A, Muggia FM: Treatment of
patients with ovarian carcinoma with pegylated liposomal
doxorubicin. Analysis of toxicities and predictors of out-
come.  Cancer 2001, 91:90-100.
16. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ:
Recurrent epithelial ovarian carcinoma: a randomized phase
III study of pegylated liposomal doxorubicin versus topote-
can.  J Clin Oncol 2001, 19:3312-22.
17. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30–49 Investi-
gators: Long-term survival advantage for women treated with
pegylated liposomal doxorubicin compared with topotecan
in a phase 3 randomized study of recurrent and refractory
epithelial ovarian cancer.  Gynecol Oncol 2004, 95:1-8.
18. Ferrero JM, Weber B, Lepille D, Orfeuvre H, Combe M, Mayer F,
Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E: Caelyx and
Carboplatin in patients with advanced ovarian cancer in late
relapse (>6 months): late results of a GINECO phase II trial
[abstract].  Proc Am Soc Clin Oncol 2004, 23:. 53 (Abstr 5022)
19. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall
FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dos-
age: prospect of evaluation of a simple formula based on
renal function.  J Clin Oncol 1989, 7:1748-56.
20. National Cancer Institute – Cancer Therapy Evaluation Pro-
gram: Common Toxicity Criteria. Version 2.0 April 30, 1999
[http://ctep.info.nih.gov]
21. du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B,
Jackisch C, Staehle A, Kimmig R, Elser G: Pegylated liposomal
doxorubicin and carboplatin in advanced gynecologic
tumors: a prospective phase I/II study of the Arbeitsgemein-
schaft Gynaekologische Onkologie Studiengruppe Ovari-
alkarzinom (AGO-OVAR).  Ann Oncol 2006, 17:93-6.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:202 http://www.biomedcentral.com/1471-2407/6/202
Page 8 of 8
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/202/pre
pub